Fondazione Irccs Istituto Nazionale Tumori

Milan 20133

0 studies enrolling now · 11 studies all time

What they study most

Advanced Lung Cancer, Bladder Cancer, Brain Tumor, Primary, Desmoplastic Small Round Cell Tumor, Esophageal Cancer, Gastric Adenocarcinoma, Gastric Cancer, Gastro-enteropancreatic Neuroendocrine Tumor, Hodgkin Lymphoma, Lung Cancer, Metastatic Lung Cancer, Metastatic Urothelial Carcinoma

Studies at this site

• Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) — Running, not enrolling
• HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer — Running, not enrolling
• (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma — Running, not enrolling
• Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET — Running, not enrolling
• Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma — Running, not enrolling
• Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors — Stopped early
• Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma — Stopped early
• A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer — Completed
• Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer — Completed
• R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma — Stopped early
• A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations — Stopped early